Samjin Pharmaceutical Signs Research and Development Agreement for Degenerative Brain Disease Treatment with Aribio

Choi Yong-ju, CEO of Samjin Pharmaceutical (left), and Jung Jae-jun, CEO of Aribio, are posing for a commemorative photo after signing a research and development agreement.

[Asia Economy Reporter Lee Gwan-joo] Samjin Pharmaceutical announced on the 18th that it has signed a strategic business agreement (MOU) for joint research and cooperation in new drug development with Aribio.

Through this agreement, Samjin Pharmaceutical and Aribio will jointly conduct research and strategic cooperation in the field of treatments for intractable diseases, discovery and development research of new drug candidates, and development of treatments for degenerative brain diseases.

Samjin Pharmaceutical will utilize the state-of-the-art facilities and research infrastructure of the Magok Research Center, completed last year, to conduct research on the discovery, synthesis, and formulation development of various new drug candidates being developed by Aribio. At the Samjin Pharmaceutical Magok Research Center, innovative drug research and development is actively underway in areas with high unmet medical needs such as cancer, fibrotic diseases, ophthalmic diseases, degenerative brain diseases, and autoimmune diseases.

Samjin Pharmaceutical also plans to link its experience in developing central nervous system disease products such as joint industry-academia research and development (new drugs for degenerative brain diseases, Alzheimer's dementia platform), the dementia treatment drug 'Newtoin' containing donepezil, and the brain function enhancer 'Nutirin' containing choline alfoscerate.

Aribio is developing treatments for degenerative brain diseases using its proprietary new drug development platform (ARIDD), with particular attention on the dementia treatment drug 'AR1001.' AR1001 has completed Phase 2 clinical trials with the U.S. Food and Drug Administration (FDA) and recently commenced global Phase 3 clinical trials. It is expected to be an innovative dementia drug with a multi-mechanism that not only inhibits dementia progression but also improves cognitive function.

Choi Yong-joo, CEO of Samjin Pharmaceutical, said, “We have formed a meaningful strategic alliance at an important time when Aribio’s AR1001, being developed as a global dementia treatment, is entering FDA Phase 3 clinical trials. We expect great results from joint research by combining our cutting-edge R&D infrastructure and expertise in developing central nervous system disease products, and we will actively pursue additional new drug pipeline development through a long-term and comprehensive mutual cooperation relationship.”

This content was produced with the assistance of AI translation services.